842133-18-0

Storage:at -20℃ 2 years

Biologieal

Canagliflozin is an experimental drug being developed by Johnson & Johnson for the treatment of type 2 diabetes.^[1][2] It is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the urine.^[3]

Reference

1. ^ New J&J diabetes drug effective in mid-stage study, Jun 26, 2010
2. ^ Edward C. Chao (2011). "Canagliflozin". Drugs of the Future 36 (5): 351-357. doi:10.1358/dof.2011.36.5.1590789. 
3. ^ Prous Science: Molecule of the Month November 2007